

**On behalf of the Chief Investigators, Professor Simon Gollins and Dr Ane Appelt and the CTRU Team, welcome to the 9<sup>th</sup> APHRODITE trial newsletter!**

### Recruitment

The trial has recruited **27** patients from across the 9 sites open to recruitment so far as of August 2022. Our ultimate target is to recruit **104** patients into the APHRODITE trial from across the 13 sites selected.

Congratulations to **Christie** and **Glan Clwyd** for recruiting 2 patients at each site so far in Q3 and to **St James's** for recruitment of their first patient! The table to the right lists the total number of patients recruited per site.

### Site Setup

We continue to support setup at sites opening to the trial. If sites have any queries or are having any difficulties with set-up, please feel free contact us via the APHRODITE trial inbox.

Recruitment Table

Site	Site Code	Total Patients Recruited
Glan Clwyd	C00353	13
Christie	C00018	6
Churchill	C00153	2
Lincoln	C00089	2
Clatterbridge	C00019	2
Weston Park	C00062	1
St James's	C00050	1
Royal Preston	C00160	0
North Tees	C00256	0

### Substantial Amendment 3

Substantial amendment 3 has now been approved and was distributed to sites 13/07/2022. The changes made in this amendment include:

- The description of patient population updated to now emphasise that the trial is open for all patients who express a strong preference for organ preservation
- Updates to patient eligibility criteria to include:
  - Patients with positive lymph nodes in the mesorectum (N1a-b)
  - Acceptable maximum tumour diameter increased to 5cm
- Addition of a central review process for baseline MRI, where the scans for the first 2 patients from each site will be reviewed centrally in real-time prior to randomisation
- Addition of Addenbrooke's and Southampton as new recruiting sites
- A new YCR logo has been incorporated throughout all documentation

If you have any queries or comments on this amendment please contact the trial inbox [APHRODITE@leeds.ac.uk](mailto:APHRODITE@leeds.ac.uk)

### Discrete Choice Experiment (DCE)

The APHRODITE patient preference project will enhance and complement the trial results by measuring what aspects of non-surgical management of colorectal cancer are most important to patients. We have recruited **22** participants so far, and **10** participants have already completed the 6-month follow-up survey.

The patient preference project is simple and easy to set up, and we are still interested in opening new sites. If you're not already recruiting for the APHRODITE patient preference project and would like to hear more, please contact [patientpreferenceAPHRODITE@leeds.ac.uk](mailto:patientpreferenceAPHRODITE@leeds.ac.uk)

If you have any questions or queries about trial setup, please contact Matthew our Trial Management Assistant by emailing the APHRODITE trial inbox at [APHRODITE@leeds.ac.uk](mailto:APHRODITE@leeds.ac.uk)



If you would like your site to be featured on the newsletter then please let us know about your experience of recruiting into the APHRODITE trial!